Bile duct cancer
single arm prospective phase II clinical trial to evaluate use of Trastuzumab emtansine as second-line therapy in HER2 positive Advanced Biliary tract cancers -(TAB-3 trial)
Who can joinAdults
Age18–75 years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbaiDirections ↗
Registry summary (technical)
Trastuzumab emtansine as second-line therapy in HER2 positive Advanced Biliary tract cancers -single arm prospective phase II clinical trial(TAB-3 trial) - TAB-3 Study
Sponsor: Tata Memorial Hospital
CTRI/2023/07/055785 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 1 Jun 2026 · read by us 5 Nov 2026